Charge variant analysis of mAb biotherapeutics by Nexera XS with a Shim-pack Bio IEX Column

Importance of the Topic

Monoclonal antibodies (mAbs) represent a cornerstone of modern biopharmaceuticals, offering targeted therapies for cancer, autoimmune, cardiovascular, respiratory and infectious diseases. Their structural complexity and post-translational modifications give rise to charge variants that can influence safety, efficacy and batch-to-batch consistency. Robust analytical methods to characterize these variants are therefore critical for quality control, regulatory compliance and the advancement of biotherapeutic development.

Aims and Study Overview

This study demonstrates a universal salt-gradient ion exchange chromatography approach for profiling charge variants of four therapeutic mAbs—trastuzumab, omalizumab, rituximab and cetuximab—using a Shimadzu Nexera XS UHPLC system and Shim-pack Bio IEX SP-NP columns. The goal was to develop a single gradient program that achieves high resolution and reproducibility across diverse mAb structures.

Methodology and Used Instrumentation

Sample Preparation

• mAb solutions (5 mg/mL) prepared in 20 mM sodium phosphate buffer, pH 6.0.
• Direct injection (2 µL) without further purification.

Chromatographic Conditions

• Column: Shim-pack Bio IEX SP-NP (100 mm × 4.6 mm I.D., 3 µm).
• Mobile phases: A—20 mM phosphate, pH 6; B—20 mM phosphate + 250 mM NaCl, pH 6.
• Gradient: 0–1.5 min (0% B), 1.5–15 min (0–100% B), 15–18 min (100% B), 18.1–20 min (0% B).
• Flow rate: 0.5 mL/min; UV detection at 280 nm; oven at 25 °C; autosampler at 15 °C.

Instrument

• Shimadzu Nexera XS UHPLC system.
• UV detector set to 280 nm.

Main Results and Discussion

All four mAbs exhibited clear separation of acidic, main and basic variants within a 20-minute run. The main peak accounted for 42–77% of total area, while acidic and basic species appeared as early or late eluting minor peaks. Six consecutive injections showed overlay chromatograms with retention time reproducibility and peak area %RSD below 5% for all variants and main components, confirming the method’s precision and robustness.

Practical Benefits and Applications

This salt-gradient IEX method provides a streamlined, consistent platform for charge heterogeneity analysis in biopharmaceutical QA/QC. Its single gradient protocol reduces method development time and ensures comparability across multiple mAbs, facilitating regulatory submissions and routine batch release testing.

Future Trends and Opportunities

Advances may include integration of pH gradients for enhanced variant resolution, automation with digital-intelligence features for self-diagnosis and system optimization, and coupling with mass spectrometry for structural elucidation. Implementation of QbD principles and AI-driven data analysis will further improve method robustness and throughput.

Conclusion

The described salt-gradient IEX approach on the Nexera XS platform with Shim-pack Bio IEX SP-NP columns delivers rapid, reproducible charge variant profiling of therapeutic mAbs. With <5% RSD and full separation in 20 minutes, it supports rigorous quality assessment and streamlined biopharma workflows.